15th RSC-SCI Medicinal Chemistry Symposium
26/08/08 13:42 Filed in: Medicinal
Chemistry
Details of 15th RSC-SCI
Medicinal Chemistry Symposium, 6-9 September 2009,
Churchill College, Cambridge, UK.
The
first circular for the 15th RSC-SCI Medicinal
Chemistry Symposium, 6-9 September 2009, Churchill
College, Cambridge, UK is now available.
Discovery of Potent and Selective Non-steroidal Glucocorticoid
Receptor Agonists
David House (GlaxoSmithKline, UK)
MC4 Agonists for the Treatment of Sexual Dysfunction
Mark Lansdell (Pfizer Global R&D, UK)
Next Generation NK -1 Antagonists
Robert DeVita (Merck, USA)
Medicinal Chemistry and Biology of E2007, an Orally -active AMPA
Receptor Antagonist, for Neurological Disorders
Koichi Ito (Eisai, Japan)
The Identification of Selective P38 Inhibitors with High Blood
Potency Suitable for Clinical Development
Vipul Patel (GlaxoSmithKline, UK)
Progressing Carboxylic Acid Leads as PDE7 Inhibitors
Nigel Swain (Pfizer Global R&D, UK)
Non -nucleoside inhibitors for the Treatment of Hepatitis C Virus
Infection
Frank Narjes (Merck Sharp & Dohme, Italy)
Potent, Non-peptidic, Orally-active Renin Inhibitors
Olivier Bezençon (Actelion Pharmaceuticals, Switzerland)
Inhibitors of GSK-3 Kinase for the Treatment of Neurodegenerative Diseases
Juan-Miguel Jimenez (Ve rtex, UK)
CarboCarrier™: A Novel Technology to Extend the Half-life of
Small Proteins and Peptides
Martin de Kort (Schering -Plough, The Netherlands)
Discovery of Potent and Selective Non-steroidal Glucocorticoid
Receptor Agonists
David House (GlaxoSmithKline, UK)
MC4 Agonists for the Treatment of Sexual Dysfunction
Mark Lansdell (Pfizer Global R&D, UK)
Next Generation NK -1 Antagonists
Robert DeVita (Merck, USA)
Medicinal Chemistry and Biology of E2007, an Orally -active AMPA
Receptor Antagonist, for Neurological Disorders
Koichi Ito (Eisai, Japan)
The Identification of Selective P38 Inhibitors with High Blood
Potency Suitable for Clinical Development
Vipul Patel (GlaxoSmithKline, UK)
Progressing Carboxylic Acid Leads as PDE7 Inhibitors
Nigel Swain (Pfizer Global R&D, UK)
Non -nucleoside inhibitors for the Treatment of Hepatitis C Virus
Infection
Frank Narjes (Merck Sharp & Dohme, Italy)
Potent, Non-peptidic, Orally-active Renin Inhibitors
Olivier Bezençon (Actelion Pharmaceuticals, Switzerland)
Inhibitors of GSK-3 Kinase for the Treatment of Neurodegenerative Diseases
Juan-Miguel Jimenez (Ve rtex, UK)
CarboCarrier™: A Novel Technology to Extend the Half-life of
Small Proteins and Peptides
Martin de Kort (Schering -Plough, The Netherlands)